SCHEMBL428793

SCHEMBL428793

Nc1nc(-c2ccc(Br)cc2)cs1

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.96
MAPT P10636 7/20 0.96
NPC1 O15118 5/20 0.96
SMN1; SMN2 Q16637 5/20 0.96
LTA4H P09960 5/20 0.83
ALDH1A1 P00352 9/20 0.66
KDM4E B2RXH2 4/20 0.66
LMNA P02545 3/20 0.66
MEN1 O00255 2/20 0.66
KMT2A Q03164 2/20 0.66
NFKB1 P19838 2/20 0.66
NFKB2 Q00653 2/20 0.66
RELA Q04206 2/20 0.66
MKNK1 Q9BUB5 1/20 0.66
MKNK2 Q9HBH9 1/20 0.66
ALOX5 P09917 1/20 0.66
HPGD P15428 1/20 0.62
HK1 P19367 1/20 0.62
HKDC1 Q2TB90 1/20 0.62
NPSR1 Q6W5P4 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL4433292 0.98 RAB9A (1.00) RAB9AMAPTNPC1SMN1; SMN2LTA4H
SCHEMBL3129591 0.91 LTA4H (1.00) RAB9AMAPTNPC1SMN1; SMN2LTA4H
SCHEMBL1771825 0.89 ALDH1A1 (0.79) RAB9AMAPTNPC1SMN1; SMN2LTA4H
SCHEMBL23610361 0.87 ALDH1A1 (0.83) RAB9AMAPTNPC1SMN1; SMN2LTA4H
SCHEMBL172279 0.83 ALDH1A1 (0.70) RAB9AMAPTNPC1SMN1; SMN2LTA4H
SCHEMBL3174725 0.83 RAB9A (0.68) RAB9AMAPTNPC1SMN1; SMN2LTA4H
Iodide SCHEMBL6175053 0.81 ALDH1A1 (0.68) RAB9AMAPTNPC1SMN1; SMN2LTA4H
SCHEMBL4986233 0.80 KDM4E (0.73) RAB9AMAPTNPC1SMN1; SMN2LTA4H
SCHEMBL128793 0.79 ALDH1A1 (1.00) RAB9AMAPTNPC1SMN1; SMN2LTA4H
SCHEMBL430121 0.79 LTA4H (0.83) RAB9AMAPTNPC1SMN1; SMN2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108640835-B Method for preparing glycerol triacetate through organic catalysis 南京工业大学 2020-08-21 CN claimed
CN-108640835-A Method for preparing glycerol triacetate through organic catalysis 南京工业大学 2018-10-12 CN claimed
EP-4688759-A1 USP2 INHIBITORS AND METHODS OF USING THE SAME FOR THE TREATMENT OF DISEASES Icahn School of Medicine at Mount Sinai (US) 2026-02-11 EP disclosed
CN-120081363-A Preparation method and application of nitrogen-sulfur-boron co-doped graphene composite material for lithium ion battery negative electrode 唐山北碳科技有限公司 2025-06-03 CN disclosed
CN-115466229-B Para-amidobenzenesulfonyl compound and application thereof 上海中医药大学 2025-01-24 CN disclosed
WO-2024211785-A1 USP2 INHIBITORS AND METHODS OF USING THE SAME FOR THE TREATMENT OF DISEASES ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2024-10-10 WO disclosed
US-12036208-B2 Methods for treating neurodegenerative disorders ALZHEON, INC. (US) 2024-07-16 US disclosed
US-12036208-B2 Methods for treating neurodegenerative disorders ALZHEON, INC. (US) 2024-07-16 US disclosed
CN-118084890-A Isoxazoline-containing pyrazole amide compound as well as preparation method and application thereof 安徽农业大学 2024-05-28 CN disclosed
US-20240115557-A1 INHIBITORS OF RNA-GUIDED NUCLEASES AND USES THEREOF THE BROAD INSTITUTE, INC. 2024-04-11 US disclosed
CN-117486872-A Mechanical ball milling synthesis method of aminothiazole compound 浙江工业大学 2024-02-02 CN disclosed
CN-1176101-A N -(4 -aryl -thiazol -2 -yl) -sulphonamide derivatives and their use HOFFMANN LA ROCHE (CH) 1998-03-18 CN disclosed
US-5714503-A Compounds and methods for inhibition of HIV and related viruses MEDIVIR AB (SE) 1998-02-03 US disclosed
EP-0819681-A2 N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use F. HOFFMANN-LA ROCHE AG (CH) 1998-01-21 EP disclosed
US-5658907-A THIOUREA VIRICIDES MEDIVIR A/B (SE) 1997-08-19 US disclosed
US-5593993-A VIRICIDES FOR HTLV TREATMENT OF AIDS MEDIVIR AB (SE) 1997-01-14 US disclosed
EP-0540143-A2 Compounds and methods for inhibition of HIV and related viruses Medivir Aktiebolag (SE) 1993-05-05 EP disclosed
WO-1993003022-A1 COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES MEDIVIR AB (SE) 1993-02-18 WO disclosed
US-4207233-A Azo dyes containing a thiazole component BASF AKTIENGESELLSCHAFT (DE) 1980-06-10 US disclosed
US-4104268-A POLYACRYLONITRILE, POLYESTERS, POLYAMIDES BAYER AKTIENGESELLSCHAFT (DE) 1978-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12036208-B2 Methods for treating neurodegenerative disorders NLN, CLN6, SNCA RAB9A 1741/4885MAPT 9/4885NPC1 151/4885
US-20240115557-A1 INHIBITORS OF RNA-GUIDED NUCLEASES AND USES THEREOF ZFR, ENDOD1, FEN1 RAB9A 2468/4885MAPT 3271/4885NPC1 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.